Addendum to Commission A12-15 (Crizotinib) [Internet].

On 15 November 2012 the Federal Joint Committee (G-BA) commissioned the Institute for Quality and Efficiency in Health Care (IQWiG) to conduct a benefit assessment of crizotinib pursuant to § 35a Social Code Book V (Commission No. A12-15). The assessment was made on the basis of a dossier of the pharmaceutical company (hereinafter abbreviated to "the company"). On 15 February 2013 the G-BA published IQWiG's dossier assessment of 13 February 2013 for comment.

http://ift.tt/2t2iFz9